The US Food and Drug Administration has granted Emergency Use Authorisation (EUA) to BioGX’s direct sample addition Xfree COVID-19 reverse transcription-polymerase chain reaction (RT-PCR) test.

A comprehensive test, Xfree COVID-19 is lyophilised in one tube, so a sample can be directly added for real-time RT-PCR testing without requiring extraction.

Xfree comes in BioGX Sample-Ready format and can be transported anywhere without needing refrigeration.

To carry out the test, the user simply rehydrates the lyophilised test with molecular grade water, then adds a patient sample and runs the test on an approved real-time PCR device.

Eradicating all the steps needed for upfront sample processing, the test helps clinical laboratories deliver high-throughput sample-to-answer results with the help of broadly available real-time PCR platforms, BioGX said.

The test is authorised by the FDA to process a variety of specimens including nasopharyngeal, anterior nasal, mid-turbinate and oropharyngeal swab samples, as well as nasopharyngeal wash/aspirate and nasal aspirates.

Furthermore, Xfree COVID-19 is authorised to run with extracted specimens, which will provide options for labs to modify the test in various workflows.

Priced between $7 to $12 per sample, based on the type of direct or extracted sample addition, the test is currently being used in many labs.

BioGX CEO Shazi Iqbal said: “Our test not only enables laboratories of all sizes to perform high-performance cost-effective testing but also provides robust strain coverage for all prevalent strains, including the rapidly spreading Delta variant.

“The FDA authorisation of our Xfree chemistry paves the way for us to leverage our expansive menu of tests to create an Xfree line of point-of-care (POC) tests for respiratory and urinary tract infections.”

In April last year, BioGX and BD received FDA EUA for a new Covid-19 test.